glp1medication.guide is an independent reference on GLP-1 receptor agonist medicines: semaglutide, tirzepatide, liraglutide and the drugs arriving behind them. It was founded in August 2026 and publishes in 16 languages. It sells nothing, takes no advertising, and has no pharmaceutical sponsor.
Who writes it
Thomas Prommer has more than 20 years of experience leading engineering and technology strategy, including Global SVP of Engineering at Adidas, Chief Information Officer at Sweetgreen and President of Technology at Huge. He is the founder of We The Flywheel, and publishes ctaio.dev and prommer.net.
The reason a technology career is worth stating on a site about medicine is what it is actually good for here: reading primary sources carefully, holding a claim to its evidence, and being willing to publish that the evidence is thin. It is not medical training and this site does not present it as any.
The second half of the relevance is not professional. He competes in HYROX in the Pro Division, the heaviest weight category for men, and has completed multiple marathons and Ironman-distance triathlons. Body composition, appetite, training load and metabolic health are subjects he tracks on himself with data, year round, which is why this site exists and why it is written for people who want the numbers rather than the reassurance.
He is not a physician, and this site says so on every page it applies to. Nothing here is a clinical opinion, a diagnosis or a recommendation about your treatment. The expertise being claimed is the research method described below and nothing beyond it. If you want a clinician's view of your own case, that is what a clinician is for.
There are other people with this name. This is the Thomas Prommer who publishes glp1medication.guide, ctaio.dev and prommer.net, born 22 April 1980. He is not either of the attorneys of the same name at Kirkland & Ellis or Milbank.
How the pages are written
Every factual claim traces to a named source, and the sources are listed at the foot of the page they support rather than gathered somewhere out of sight. In practice that means three kinds of document: regulator-approved prescribing information (the FDA and EMA labels for each drug), peer-reviewed trial publications and systematic reviews, and the manufacturers' own published materials where the question is what a manufacturer states. Where a page uses a number, the number comes from one of those, and the date the sources were last read is printed with them.
Where sources disagree, the page says so rather than picking the tidier answer. Where a claim is common online and unsupported, the page says that too. That is the most useful thing a reference like this can do.
What has not been reviewed
No clinician has checked these pages. Most pages carry that sentence explicitly, directly under the credit, and it is not boilerplate: it is the accurate description of the site's current state. Pages that touch subjects where the risk of unreviewed content is highest are flagged internally and held. We would rather publish an honest disclosure than an implied authority we have not bought.
Corrections
If something here is wrong, we want to know, and a correction with a source attached will be made. Write to [email protected]. Corrections are made on the page itself, and the sources-last-read date moves when they are.
Related
Privacy policy — what the site collects, which is usage analytics and nothing you type.